SLC2A1 and soft tissue sarcoma: (2) In soft-tissue sarcomas, glycolytic CAFs (GLUT1-dependent) secrete CXCL16, which traps CD8+ T cells at the margins and limits treatment penetration; dampening glycolysis reduces the CXCL16 barrier, restores intratumoral T cell trafficking, and enhances responses to chemotherapy (and ICB).